Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 8.

Doebele, R., Ahn, M., Siena, S., Drilon, A., Krebs, M., Lin, C., De Braud, F., John, T., Tan, D., Seto, T., Dziadziuszko, R., Arkenau, H., Barlesi, F., Rolfo, C., Wolf, J., Chow-Maneval, E., Multani, P., Cui, N., Riehl, T. and Cho, B. C. (2018). Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 13 (10). S. S321 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Goto, K., Oxnard, G., Tan, Shao-Weng D. S. W., Loong, Ho Fung H., Bauer, T. T., Gainor, J., McCoach, C., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y., Ohe, Y., Horiike, A., Park, K., Huang, X., Olek, E., Subbiah, V, Drilon, A. and Wolf, J. (2021). Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC). Pneumologie, 75. S. S42 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Joerger, M., Soo, R., Cho, B. C., Navarro Mendivil, A., Sayehli, C., Richly, H., Tai, D., Kim, D. -W., Wolf, J., Cassier, P., Ellinghaus, P., Hildebrandt, S., Behre, S., Helmbrecht, C., Kerpen, S., Zielinski, D., Ince, S., Rajagopalan, P., Ocker, M. and Schuler, M. (2016). Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Schuler, M., Nogova, L., Heidenreich, A., Tai, D., Cassier, P., Richly, H., Cho, B. C., Sayehli, C. M., Navarro, A., Bender, S., Ocker, M., Nogai, H., Wagner, A., Ince, S., Ellinghaus, P. and Joerger, M. (2017). Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Wolf, J., Liu, S. V., Paz-Ares, L., Hu, J., Cho, B. C., Krzakowski, M., Chung, C. H., Patel, M., Taylor, M., Zeuner, H., Aziez, A., Huang, X., Osborne, S. and Farago, A. (2020). Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001. Oncol. Res. Treat., 43 (SUPPL 4). S. 34 - 35. BASEL: KARGER. ISSN 2296-5262

This list was generated on Fri Mar 29 07:28:33 2024 CET.